Clinical Trial

Best Chocolate Weight Loss Supplement: Consumer Analysis Examines Cacao GLP-1 Research as January Wellness Interest Surges

Consumer analysis evaluates Earth Echo Cacao Bliss ingredient disclosures, ceremonial-grade processing claims, and published GLP-1 research frequently referenced in chocolate-based…

1 month ago

CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

Engagement reinforces CDT’s strategy to unlock value from its solid-form asset portfolioNAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 02, 2026…

1 month ago

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…

1 month ago

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new…

1 month ago

Mesoblast Announces Changes to Board of Directors’ Leadership Roles

NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…

1 month ago

Best ACV Gummies 2026 Report: True Keto Fusion Analyzed in New Year Keto-ACV Industry Analysis

An Informational Buyer's Guide to Apple Cider Vinegar Gummies, BHB Ketogenic Support Ingredients, Weight Wellness Formulations, and What Label Transparency…

1 month ago

Best Keto Gummies for 2026: BHB Supplement Guide Examines What Consumers Should Know Before Buying

Revra Keto BHB Gummies highlighted among ketogenic supplements as independent analysis examines full spectrum BHB formulations, exogenous ketone research, consumer…

1 month ago

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

Clinical Data doubles known genetic factors associated with urate and GoutCALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics…

1 month ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.…

1 month ago